GSK plc (LSE:GSK) reported third-quarter turnover of £8,887m, up 4% at actual exchange rates, and reaffirmed 2026 guidance that points to the upper half of its turnover and core operating profit growth ranges.

What was announced

GSK published its third-quarter results on 28 October 2026. Turnover for the quarter rose 4% to £8,887m, or 5% at constant exchange rates (CER). For the first nine months, turnover reached £24,925m, also up 4% (5% CER).

Core operating profit rose 3% to £3,076m (5% CER), giving a core operating margin of 34.6%. Core earnings per share were 54.6p, down 1% at actual rates but up 1% at CER. Over nine months, core EPS was 151.6p, up 4% (6% CER).

On a total (statutory) basis, the picture was weaker. Total operating profit fell 18% to £2,127m and total EPS declined 23% to 38.5p. The company attributed part of the gap to Major Restructuring charges of £328m linked to its Accelerate Growth programme, and to other operating expense of £262m, which included a £289m remeasurement charge on contingent consideration liabilities.

The numbers by segment

Specialty Medicines was the main driver, with sales up 14% to £3,877m (15% CER). Within it, HIV sales rose 9% to £2,116m, Respiratory, Immunology and Inflammation grew 19% to £1,139m, and Oncology increased 22% to £622m.

Vaccines sales fell 4% to £2,583m (down 2% CER). Shingrix sales were £780m, down 6%, and Arexvy fell 22% to £195m, while Meningitis vaccines rose 11% to £599m. General Medicines was broadly stable at £2,427m, down 1% (flat at CER), with Trelegy up 7% to £787m.

By region, US sales rose 8% to £4,931m, Europe grew 3% to £1,928m and International declined 4% to £2,028m.

Cash generated from operations increased 24% to £3,122m, and free cash inflow was £2,078m against £1,246m a year earlier. Total net debt stood at £20,739m at 30 September 2026, up from £14,453m at the end of 2025. GSK (LSE:GSK) said the increase mainly reflected acquisitions, including Nuvalent (£7,143m), RAPT (£1,404m) and 35Pharma (£700m).

The board declared a third-quarter dividend of 17p per share and said it expects to pay 70p for the full year 2026. The £2bn share buyback announced with the 2024 full-year results has been completed.

Guidance and pipeline

GSK reaffirmed its 2026 guidance at CER. The company expects turnover growth of 3% to 5% and core operating profit growth of 7% to 9%, in both cases in the upper half of the range. Core EPS growth is guided at 7% to 9%, in the lower half of the range. GSK also expects Specialty Medicines to grow at a low double-digit % rate, Vaccines to be broadly stable or show a low single-digit increase, and General Medicines to decline at a mid- to low single-digit rate.

GSK said it remains on track for its 2031 sales outlook of more than £40bn. On currency, it estimated that exchange rates at 30 September 2026 would reduce 2026 turnover growth by about 1% point and core operating profit growth by about 3% points.

Chief Executive Luke Miels said GSK had delivered another quarter in which its key growth drivers and new launches performed well. He pointed to three recent US approvals in specialty medicines: Hibsago for chronic hepatitis B, Jemperli for dMMR/MSI-H locally advanced rectal cancer, and Jideytro for second-line ROS1-positive non-small cell lung cancer. GSK has started 18 of the 22 phase III trials it plans to begin in 2026, including a phase III study of an mRNA seasonal flu vaccine.

What to watch next

The company listed several milestones for the second half of 2026: the phase III OCEAN readout for Exdensur in EGPA, a US regulatory decision on neladalkib in pre-treated ALK-positive lung cancer, and a US submission for Jideytro in treatment-naive ROS1-positive lung cancer. A results call and webcast hosted by Mr Miels was scheduled for 12:00 GMT on 28 October.